A breakthrough study at the American Foregut Society Meeting 2025 revealed that an AI-enabled spatial proteomics test outperforms standard assessments in determining the progression risk of Barrett’s esophagus (BE), a precursor to esophageal adenocarcinoma (EAC). With EAC's low five-year survival rate of 22 percent, accurate risk stratification is crucial. The spatial proteomics test identifies subtle changes in tissue that traditional pathology may miss, enabling earlier interventions like endoscopic eradication therapy, ultimately improving patient outcomes by aligning care decisions with individual risk profiles.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
